Sanofi Acquires Biogen's Bioverativ
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
On March 8, 2018, Sanofi announced that it has acquired Bioverativ, Biogen’s hemophilia and blood disorders-focused company, for $105 per share in cash.
Initially announced in January 2018, this acquisition strengthens Sanofi's position in hematology and specialty medicines by adding Bioverativ's Eloctate (recombinant fusion protein composed of human immunoglobulin[IG] G1-Fc linked cleavage factor VIII) and Alprolix (recombinant fusion protein composed of IX coagulation factor IX Fc fragment of IgG1) for the treatment of hemophilia A and hemophilia B, respectively, to Sanofi’s hemophilia portfolio. Bioverativ produced $1.17 billion in sales in 2017.
“The addition of Bioverativ provides us with a strong position in the large and growing hemophilia market and expands our presence in specialty care,” said Olivier Brandicourt, CEOß at Sanofi, in a company press release. “Through a series of three strategic transactions-the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran-we are well on our way to creating a leading franchise in the field of rare blood disorders.”
Source: Sanofi
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
